Immunic Inc (NASDAQ:IMUX) has a beta value of 1.86 and has seen 1.11 million shares traded in the last trading session. The IMUX stock price is -50.71% off its 52-week high price of $2.11 and 32.14% above the 52-week low of $0.95. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.37 million shares traded. The 3-month trading volume is 389.27K shares.
The consensus among analysts is that Immunic Inc (IMUX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.22.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Immunic Inc (NASDAQ:IMUX) trade information
Over the past 30 days, the shares of Immunic Inc (NASDAQ:IMUX) have changed -6.04%. Short interest in the company has seen 2.68 million shares shorted with days to cover at 4.77.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 72.0% from current levels. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the current price level is -257.14% off the targeted high while a plunge would see the stock gain -257.14% from current levels.
Immunic Inc (IMUX) estimates and forecasts
Figures show that Immunic Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -2.78% over the past 6 months, with this year growth rate of 54.98%, compared to 17.40% for the industry.
4 analysts offering their estimates for the company have set an average revenue estimate of 10k for the current quarter. 4 have an estimated revenue figure of 10k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 31.12% over the past 5 years. Earnings growth for 2024 is a modest 56.87% while over the next 5 years, the company’s earnings are expected to increase by 15.50%.
IMUX Dividends
Immunic Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Immunic Inc (NASDAQ:IMUX)’s Major holders
Insiders own 3.34% of the company shares, while shares held by institutions stand at 62.51% with a share float percentage of 64.67%. Investors are also buoyed by the number of investors in a company, with Immunic Inc having a total of 70.0 institutions that hold shares in the company. The top two institutional holders are BVF INC/IL with over 8.9 million shares worth more than $9.88 million. As of 2024-06-30, BVF INC/IL held 9.15% of shares outstanding.
The other major institutional holder is AVIDITY PARTNERS MANAGEMENT LP, with the holding of over 8.9 million shares as of 2024-06-30. The firm’s total holdings are worth over $9.88 million and represent 9.15% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund . As of Jun 30, 2024 , the former fund manager holds about 2.08% shares in the company for having 1.87 shares of worth $2.62 million while later fund manager owns 1.67 shares of worth $2.34 million as of Jun 30, 2024 , which makes it owner of about 1.85% of company’s outstanding stock.
